secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001193125-24-222962
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences appoints Richard Vincent and Shiv Kapoor to board; settles Camac lawsuit for $1.5M
--------------------------------------------------------------------------------

- Donald A. Williams and Lawrence Eichenfield resigned from board effective Sept 17, 2024, not due to any disagreement.
- Richard Vincent and Shiv Kapoor appointed as Class II directors; to stand for election at 2025 annual meeting.
- Steven Kornfeld and Scott Brun reclassified from Class II to Class III to maintain class sizes.
- Camac Fund lawsuit settled; company to pay $1.5M for attorneys' fees; case dismissed with prejudice as to Camac; Standstill Agreement stands.
- Board established Strategic Committee of independent directors; Rights Agreement (poison pill) expired July 12, 2024, not renewed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/0001193125-24-222962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/d844019d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-222962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer